This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Reduction of the Dietary Glycemic Index (GI) by L-Arabinose and Indigestible Dextrin

This study has been completed.
Unitika Ltd.
Information provided by:
Hiroshima University Identifier:
First received: December 24, 2009
Last updated: June 22, 2011
Last verified: June 2011
This study aims to investigate the effect of supplement containing L-arabinose and indigestible dextrin on dietary glycemic index.

Condition Intervention
Healthy Dietary Supplement: L-arabinose and indigestible dextrin Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Effects of the Combination of L-Arabinose and Indigestible Dextrin on Glycemic Index: a Double-Blind, Crossover Trial

Further study details as provided by Hiroshima University:

Primary Outcome Measures:
  • Postprandial glucose level [ Time Frame: 2 hours ]

Enrollment: 19
Study Start Date: December 2009
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oolong tea containing L-arabinose and indigestible dextrin Dietary Supplement: L-arabinose and indigestible dextrin
Placebo Comparator: Oolong tea Dietary Supplement: Placebo


Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy as based on medical history and physical examination
  • BMI is less or equal to 30 kg/m2
  • Willing not to serve as blood donor during the study
  • Informed consent signed

Exclusion Criteria:

  • Impaired Glucose Tolerance
  • Female subjects who are pregnant or nursing a child
  • Participation in any clinical trial up to 90 days before Day 1 of this study
  • Renal or hepatic dysfunction
  • Heart disease
  • Under medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01039662

Hiroshima University
Hiroshima, Japan, 734-8551
Sponsors and Collaborators
Hiroshima University
Unitika Ltd.
  More Information

Responsible Party: Fumiko Higashikawa, Associate professor, Hiroshima University Identifier: NCT01039662     History of Changes
Other Study ID Numbers: eki-199
Study First Received: December 24, 2009
Last Updated: June 22, 2011 processed this record on August 17, 2017